Paratek Pharmaceuticals, Inc. announced the addition of two experienced pharmaceutical executives to the company's senior leadership team to meet the company's growing needs as it advances the development program for its lead investigational antibiotic, omadacycline, and as it expands the company's pre-commercialization capabilities. Yulii Bogatyrenko joins Paratek as Senior Vice President, Business Development, and Randall Brenner joins as Senior Vice President of Regulatory Affairs and Quality. Mr. Bogatyrenko will develop and implement corporate development strategies to support Paratek's business growth, including potential licensing partnerships.

Most recently, he was managing partner at Atem Capital. Mr. Brenner will be responsible for Paratek's Regulatory and Quality activities with all products in the development pipeline with a specific focus on advancing the Phase 3 program and the global regulatory registration process for omadacycline. Mr. Brenner has more than 20 years' experience the development and registration of products across many different regions and therapeutic areas, including anti-infectives.

He was most recently Global Head of Regulatory Affairs at Shire Pharmaceuticals.